Recent outbreaks of hantavirus, including Andes virus strains causing severe Hantavirus Pulmonary Syndrome, have heightened research focus but have not accelerated any candidates past early development stages. As of May 2026, all known efforts—such as DNA-based vaccines showing neutralizing antibodies in small Phase 1 human trials and mRNA platforms still limited to preclinical mouse studies—remain far from Phase 3 completion or regulatory review. Standard clinical timelines, which require sequential safety and efficacy data plus large-scale trials, make U.S. Food and Drug Administration approval before year-end 2026 unrealistic without an unprecedented global funding surge comparable to Operation Warp Speed. Trader consensus at 91.5% for no vaccine reflects this pipeline reality, though unexpected breakthrough funding or compressed trial designs could theoretically shift timelines if new data emerge rapidly.